Pancreaticoduodenectomy (PD) remains the only curative treatment available for pancreatic and periampullary tumor. Even with major progress in the standardization of the technique (perioperative care, anesthesiology, and surgery), PD is still associated with a high rate of postoperative morbidity, inducing prolonged hospital stay, high hospital cost, and altered quality of life.
1-4 Above all, postoperative morbidity alters oncologic results owing to both delayed chemotherapy (until impossibility of realization) and promoted tumor recurrence.
5